Showing results (231-240 of 276) with videos related to

Sort By:
Pageof 28
BMC Cancer|October 16, 2024
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtypePhilipp Ziegler, Andreas D Hartkopf, Markus Wallwiener, et al.
Breast (Edinburgh, Scotland)|November 4, 2017
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registryAndreas D Hartkopf, Jens Huober, Bernhard Volz, et al.
European Journal of Cancer (Oxford, England : 1990)|August 8, 2025
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancerLaura L Michel, Philipp Ziegler, Philipp Kreis, et al.
Geburtshilfe Und Frauenheilkunde|October 3, 2022
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients - Data from the Real-World Registry PRAEGNANTTobias Engler, Peter A Fasching, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|March 27, 2025
Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence riskVolkmar Müller, Manuel Hörner, Marc Thill, et al.
Breast (Edinburgh, Scotland)|September 21, 2020
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in GermanyAndreas Schneeweiss, Johannes Ettl, Diana Lüftner, et al.
Breast (Edinburgh, Scotland)|February 14, 2025
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancerChristina B Walter, Andreas D Hartkopf, Alexander Hein, et al.
Plos One|October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)Philipp Harter, Jan Hauke, Florian Heitz, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|September 16, 2022
Functional characteristics of a broad spectrum of TBX6 variants in Mayer-Rokitansky-Küster-Hauser syndromeCongcong Ma, Na Chen, Angad Jolly, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
CDK4/6 Inhibition - Therapy Sequences and the Quest to Find the Best Biomarkers - an Overview of Current ProgramsAndreas Schneeweiss, Sara Y Brucker, Hanna Huebner, et al.
Pageof 28